Pharmaceutical company Bridge Therapeutics revealed on Tuesday the addition of Edward J. Minskoff to its board of directors.
Currently, Minskoff is a member of NYU Langone Medical Center, Trustee, NYU Langone Medical Center, Finance Committee Member, vice chair of NYU School of Medicine Foundation's Board of Trustees, NYU Cancer Institute's Board of Directors and NYU Real Estate Institute's Advisory Board.
Minskoff is also a member of Columbia University Graduate School of Architecture and Planning, Real Estate Development advisory board; Real Estate Board of New York, Governor; The Real Estate Roundtable's board of directors; Realty Foundation of New York, Director; Partnership for New York City, Board Member; Association of Builders and Owners; Urban Land Institute, Mixed/Use Council; Metropolitan Museum of Art, Real Estate Council; Metropolitan Museum of Art, Friends of Modern Art, Founding Member; and Lincoln Center for the Performing Arts, Steering Committee.
According to the company, Minskoff brings to the board decades of financial and business experience. He is known for his philanthropy work in NYU Medical Center, as well as being involved in numerous cultural and educational institutions, including Columbia University and his alma mater, Michigan State University.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis